Literature DB >> 19864585

Effects of the antipsychotic risperidone on dopamine synthesis in human brain measured by positron emission tomography with L-[beta-11C]DOPA: a stabilizing effect for dopaminergic neurotransmission?

Hiroshi Ito1, Harumasa Takano, Hidehiko Takahashi, Ryosuke Arakawa, Michie Miyoshi, Fumitoshi Kodaka, Masaki Okumura, Tatsui Otsuka, Tetsuya Suhara.   

Abstract

Effects of antipsychotic drugs have widely been considered to be mediated by blockade of postsynaptic dopamine D(2) receptors. Effects of antipsychotics on presynaptic functions of dopaminergic neurotransmission might also be related to therapeutic effects of antipsychotics. To investigate the effects of antipsychotics on presynaptic functions of dopaminergic neurotransmission in relation with occupancy of dopamine D(2) receptors, changes in dopamine synthesis capacity by antipsychotics and occupancy of dopamine D(2) receptors were measured by positron emission tomography (PET) in healthy men. PET studies using [(11)C]raclopride and L-[beta-(11)C]DOPA were performed under resting condition and oral administration of single dose of the antipsychotic drug risperidone on separate days. Although occupancy of dopamine D(2) receptors corresponding dose of risperidone was observed, the changes in dopamine synthesis capacity by the administration of risperidone were not significant, nor was the relation between the occupancy of dopamine D(2) receptors and these changes. A significant negative correlation was observed between the baseline dopamine synthesis capacity and the changes in dopamine synthesis capacity by risperidone, indicating that this antipsychotic can be assumed to stabilize the dopamine synthesis capacity. The therapeutic effects of risperidone in schizophrenia might be related to such stabilizing effects on dopaminergic neurotransmission responsivity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19864585      PMCID: PMC6665007          DOI: 10.1523/JNEUROSCI.4172-09.2009

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  15 in total

1.  Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies.

Authors:  Paolo Fusar-Poli; Andreas Meyer-Lindenberg
Journal:  Schizophr Bull       Date:  2012-01-26       Impact factor: 9.306

Review 2.  Epigenetics and biomarkers in the staging of neuropsychiatric disorders.

Authors:  Trevor Archer; Richard J Beninger; Tomas Palomo; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2010-03-17       Impact factor: 3.911

3.  Effects of repeated and acute aripiprazole or haloperidol treatment on dopamine synthesis in the dorsal striatum of young rats: comparison to adult rats.

Authors:  Taleen Der-Ghazarian; Sergios Charntikov; Fausto A Varela; Cynthia A Crawford; Sanders A McDougall
Journal:  J Neural Transm (Vienna)       Date:  2010-04-06       Impact factor: 3.575

4.  Influence of O-methylated metabolite penetrating the blood-brain barrier to estimation of dopamine synthesis capacity in human L-[β-(11)C]DOPA PET.

Authors:  Keisuke Matsubara; Yoko Ikoma; Maki Okada; Masanobu Ibaraki; Tetsuya Suhara; Toshibumi Kinoshita; Hiroshi Ito
Journal:  J Cereb Blood Flow Metab       Date:  2013-11-06       Impact factor: 6.200

5.  Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[β-11C]DOPA.

Authors:  Hiroshi Ito; Harumasa Takano; Ryosuke Arakawa; Hidehiko Takahashi; Fumitoshi Kodaka; Keisuke Takahata; Tsuyoshi Nogami; Masayuki Suzuki; Tetsuya Suhara
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

6.  Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children.

Authors:  Ida Aka; Christiana J Bernal; Robert Carroll; Angela Maxwell-Horn; Kazeem A Oshikoya; Sara L Van Driest
Journal:  J Pers Med       Date:  2017-11-02

7.  Dopamine dysregulation in psychotic relapse after antipsychotic discontinuation: an [18F]DOPA and [11C]raclopride PET study in first-episode psychosis.

Authors:  Seoyoung Kim; Sang Ho Shin; Barbara Santangelo; Mattia Veronese; Seung Kwan Kang; Jae Sung Lee; Gi Jeong Cheon; Woojoo Lee; Jun Soo Kwon; Oliver D Howes; Euitae Kim
Journal:  Mol Psychiatry       Date:  2020-09-14       Impact factor: 15.992

Review 8.  New and emerging treatments for symptomatic tardive dyskinesia.

Authors:  Abdul Qayyum Rana; Zishan M Chaudry; Pierre J Blanchet
Journal:  Drug Des Devel Ther       Date:  2013-11-06       Impact factor: 4.162

Review 9.  CYP2D6 polymorphisms and their influence on risperidone treatment.

Authors:  Apichaya Puangpetch; Natchaya Vanwong; Nopphadol Nuntamool; Yaowaluck Hongkaew; Monpat Chamnanphon; Chonlaphat Sukasem
Journal:  Pharmgenomics Pers Med       Date:  2016-12-01

Review 10.  Presynaptic dopaminergic function: implications for understanding treatment response in psychosis.

Authors:  I Bonoldi; O D Howes
Journal:  CNS Drugs       Date:  2014-07       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.